Emyria Ltd (ASX:EMD) MD Michael Winlo speaks with Proactive after announcing the company has received strong support for its recent placement, securing firm commitments from new and sophisticated investors to raise $2 million (before costs). Alongside the oversubscribed placement, Emyria is also undertaking an entitlement offer to raise around $3.1 million at the same terms. Emyria intends to use the funds raised from the placement and entitlement offer to support its strategic objectives in mental healthcare, particularly in new drug development and in addressing the needs of the estimated 400,000 Australians impacted by severe PTSD.
Emyria provides unique combination of drug development and therapy delivery
